ARQ 531

Drug Profile

ARQ 531

Alternative Names: ARQ531

Latest Information Update: 04 May 2017

Price : $50

At a glance

  • Originator ArQule
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 26 Apr 2017 ArQule receives patent allowance for ARQ 531 in USA
  • 11 Apr 2017 US FDA approves IND application for ARQ 531 in B-cell malignancies
  • 09 Mar 2017 ArQule has patent protection for ARQ 531 (ArQule's form 10-K, filed in March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top